我国HIV-1主要流行毒株感染者中和免疫和免疫逃逸分析
摘要
HIV病毒感染机体后产生的保护性免疫反应知之甚少,这对设计有效的AIDS疫苗是个巨大的挑战。此外,我国HIV流行毒株与欧美、非洲流行毒株不同,我国流行毒株主要包括B'/C重组和B'亚型。我们对B'/C重组和B'亚型HIV-1感染者的中和免疫进行了系统研究,并从gp120基因方面探讨HIV病毒中和免疫的逃逸机制。
从我国不同流行地区HIV-1感染者中收集新鲜血,分离感染者血浆和PBMC。利用国际上公认的TZM-bl细胞系方法检测感染者血浆的中和免疫;ELISA方法检测感染者血浆对SHIV_(chn19)Env单肽的结合抗体水平。采用传统的共培养法分离临床病毒;GHOST细胞系测定分离毒株的辅助受体利用;TZM-bl细胞系检测分离毒株的中和敏感性;巢式RT-PCR扩增分离毒株gp120序列;Bioedit和MEGA软件分析氨基酸序列。
结论:1.对实验室标准毒株和临床分离毒株,B'/C感染者血浆中和水平均低于B'感染者血浆。2.HIV-1感染者血浆对同亚型内的临床分离病毒同源中和作用较好,而亚型间异源中和作用普遍偏低。3.存在部分感染者血浆有相对广谱的中和活性。4.HIV-1病毒可逃逸自身血浆的中和免疫。但是存在能被自身血浆低水平中和的分离病毒。5.感染者血浆对SHIV_(chn19)Env单肽的结合抗体水平和血浆中和活性之间未发现相关关系。6.HIV-1感染者血浆中和水平和相对应的分离毒株的中和敏感性之间存在负相关关系。7.gp120区N-糖基化位点增多是临床分离毒株逃逸机体中和免疫压力的机制之一。8.V3区序列的不同决定B'/C重组毒株利用CCR5辅助受体,而B'亚型毒株可从利用CCR5辅助受体转向利用CXCR4辅助受体。
本研究首次对我国广泛流行的HIV-1B'/C重组以及B'亚型感染者的中和免疫、临床分离毒株的中和敏感性进行了系统分析,并从分子水平探讨临床分离毒株的中和免疫逃逸机制。该结果为更好地理解HIV的致病机制,研制有效的AIDS疫苗提供了重要的参考价值。
The protective immune response of HIV-1 infected individuals is still unclear.In China,the epidemic HIV strains included B'/C recombinant and subtype B' were different form those of Europe and Africa.We just study the neutralization respongse of HIV-1 infected individuals,and try to explain the escape mechanism from gp120 sequence.
Plasmas from HIV-1 infected individuals in different epidemic area(Xinjiang Vygur Autonomous Region and Anhui province) were collected.Neutralization response of B'/C recombinant and subtype B'infected individuals detected by TZM-bl cell line;Binding antibody to SHIVchn19Env peptide of plasmas tested by ELISA. Coculture with negative PBMC to isolate clinical viruses;GHOST cell line analysis the coreceptor usage;gp120 sequences were expanded by RT-PCR and anlysised by bioedit software.
Collusions:1.The neutralization level of plasmas from HIV-1 B'/C recombinant infected individuals were lower than that of plasmas form subtype B'infected individuals.2.The intrasubtype neutralization level of plasma was higher than intersubtype neutralization level.3.It has been found few plasma from HIV-1 infected individuals have higher and broadly cross neutralization level.4.Most HIV infected individuals could not neutralize the autologous isolates;however,there were few HIV infected individuals could neutralize autologous isolate with low level.5.There were no correlation between binding antibody and neutralization level of plasmas from HIV-1 infected individuals.6.There were negative correlation between neutralization sensitivity of HIV-1 isolates and neutralization level of plasmas from infected individuals.7.HIV-1 isolates could escape the neutralization pressure by adding N-glycans of gp 120 region.8.V3 structure determined the coreceptor usage.
We first study the neutralization response of B'/C recombinant and B' subtype infected individuals.And try to explore the escape mechanism of isolates.This may help to develop the more effective AIDS vaccine.
从我国不同流行地区HIV-1感染者中收集新鲜血,分离感染者血浆和PBMC。利用国际上公认的TZM-bl细胞系方法检测感染者血浆的中和免疫;ELISA方法检测感染者血浆对SHIV_(chn19)Env单肽的结合抗体水平。采用传统的共培养法分离临床病毒;GHOST细胞系测定分离毒株的辅助受体利用;TZM-bl细胞系检测分离毒株的中和敏感性;巢式RT-PCR扩增分离毒株gp120序列;Bioedit和MEGA软件分析氨基酸序列。
结论:1.对实验室标准毒株和临床分离毒株,B'/C感染者血浆中和水平均低于B'感染者血浆。2.HIV-1感染者血浆对同亚型内的临床分离病毒同源中和作用较好,而亚型间异源中和作用普遍偏低。3.存在部分感染者血浆有相对广谱的中和活性。4.HIV-1病毒可逃逸自身血浆的中和免疫。但是存在能被自身血浆低水平中和的分离病毒。5.感染者血浆对SHIV_(chn19)Env单肽的结合抗体水平和血浆中和活性之间未发现相关关系。6.HIV-1感染者血浆中和水平和相对应的分离毒株的中和敏感性之间存在负相关关系。7.gp120区N-糖基化位点增多是临床分离毒株逃逸机体中和免疫压力的机制之一。8.V3区序列的不同决定B'/C重组毒株利用CCR5辅助受体,而B'亚型毒株可从利用CCR5辅助受体转向利用CXCR4辅助受体。
本研究首次对我国广泛流行的HIV-1B'/C重组以及B'亚型感染者的中和免疫、临床分离毒株的中和敏感性进行了系统分析,并从分子水平探讨临床分离毒株的中和免疫逃逸机制。该结果为更好地理解HIV的致病机制,研制有效的AIDS疫苗提供了重要的参考价值。
The protective immune response of HIV-1 infected individuals is still unclear.In China,the epidemic HIV strains included B'/C recombinant and subtype B' were different form those of Europe and Africa.We just study the neutralization respongse of HIV-1 infected individuals,and try to explain the escape mechanism from gp120 sequence.
Plasmas from HIV-1 infected individuals in different epidemic area(Xinjiang Vygur Autonomous Region and Anhui province) were collected.Neutralization response of B'/C recombinant and subtype B'infected individuals detected by TZM-bl cell line;Binding antibody to SHIVchn19Env peptide of plasmas tested by ELISA. Coculture with negative PBMC to isolate clinical viruses;GHOST cell line analysis the coreceptor usage;gp120 sequences were expanded by RT-PCR and anlysised by bioedit software.
Collusions:1.The neutralization level of plasmas from HIV-1 B'/C recombinant infected individuals were lower than that of plasmas form subtype B'infected individuals.2.The intrasubtype neutralization level of plasma was higher than intersubtype neutralization level.3.It has been found few plasma from HIV-1 infected individuals have higher and broadly cross neutralization level.4.Most HIV infected individuals could not neutralize the autologous isolates;however,there were few HIV infected individuals could neutralize autologous isolate with low level.5.There were no correlation between binding antibody and neutralization level of plasmas from HIV-1 infected individuals.6.There were negative correlation between neutralization sensitivity of HIV-1 isolates and neutralization level of plasmas from infected individuals.7.HIV-1 isolates could escape the neutralization pressure by adding N-glycans of gp 120 region.8.V3 structure determined the coreceptor usage.
We first study the neutralization response of B'/C recombinant and B' subtype infected individuals.And try to explore the escape mechanism of isolates.This may help to develop the more effective AIDS vaccine.
引文
1.Cohen,J.2007.AIDS research.Did Merck's failed HIV vaccine cause harm? Science 318:1048-9.
2.Paul,W.E.1995.Can the immune response control HIV infection? Cell 82:177-82.
3.Pilgrim,A.K.,G.Pantaleo,O.J.Cohen,L.M.Fink,J.Y.Zhou,J.T.Zhou,D.P.Bolognesi,A.S.Fauci,and D.C.Montefiori.1997.Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.J Infect Dis 176:924-32
4.Arendrup,M.,C.Nielsen,J.E.Hansen,C.Pedersen,L.Mathiesen,and J.O.Nielsen.1992.Autologous HIV-1 neutralizing antibodies:emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies.J Acquir Immune Defic Syndr 5:303-7
5.Moog,C,H.J.Fleury,I.Pellegrin,A.Kirn,and A.M.Aubertin.1997.Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.J Virol 71:3734-41.
6.Cao,Y,L.QIN,and L.ZHANG.1995.VIROLOGIC AND IMMUNOLOGIC CHARACTERIZATION OF LONG-TERM SURVIVORS OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION.THE NEW ENGLAND JOURNAL OF MEDICINE 332:201-208.
7.Harrer,T.,E.Harrer,S.A.Kalams,T.Elbeik,S.I.Staprans,M.B.Feinberg,Y.Cao,D.D.Ho,T.Yilma,A.M.Caliendo,R.P.Johnson,S.P.Buchbinder,and B.D.Walker.1996.Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection.AIDS Res Hum Retroviruses 12:585-92
8.McMichael AJ,Hanke T.HIV vaccines 1983-2003.
9.Nat Med,2003;9(7):874-880.Watanabe ME.Skeptical scientists skewer VaxGen statistics.Nat Med,2003;9(4):376
10.Rollman,E.,J.Hinkula,J.Arteaga,B.Zuber,A.Kjerrstrom,M.Liu,B.Wahren,and K.Ljungberg.2004.Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies.Gene Ther 11:1146-54
11.Ferrantelli F,Rasmussen RA,Buckley KA,Li PL,Wang T,et al.Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies.J Infect Dis.2004;189:2167-2173.
12.Mascola JR,Stiegler G,VanCott TC,Katinger H,Carpenter CB,et al.Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.Nat Med.2000;6:207-210.
13.Parren PW,Marx PA,Hessell AJ,Luckay A,Harouse J,et al.Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.J Virol.2001;75:8340-8347
14.Shibata R,Igarashi T,Haigwood N,Buckler-White A,Ogert R,et al.Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.Nat Med.1999;5:204-210.
15.Vertical HIV-1 transmission:importance of neutralizing antibody titer and specificity.V Bongertz,CI Costa,VG Veloso,Scand J Immunol,2001;53(3):302-9
16.Zwick MB,Labrijn AF,Wang M,Spenlehauer C,Saphire EO,Binley JM,Moore JP,Stiegler G,Katinger H,Burton DR et al.:Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1glycoprotein gp41.J Virol 2001,75:10892-10905.
17.Xu W,Smith-Franklin BA,Li PL,Wood C,He J,Du Q,Bhat GJ,Kankasa C,Katinger H,Cavacini LA et al.Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B.J Hum Virol 2001,4:55-61.
18.Zwick MB,Wang M,Poignard P,Stiegler G,Katinger H,Burton DR,Parren PW:Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.J Virol 2001,75:12198-12208.
19.Verrier F,Nadas A,Gorny MK,Zolla-Pazner S:Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6.J Virol 2001,75:9177-9186.
20.Shao Y.Report on the 2nd National HIV MolecularEpidemiology Survey.Basic Science Update by ChineseMinistry of Science and Technology 2004;5:16-18.
21.关琪,邢辉,邵一鸣,等.我国HIV-1 B′亚型毒株gag基因变异特征研究.第二届世界华人临床生化和检验医学大会论文汇编,2004,348-351.
22.liying Ma,Yanfang Guo,Lin Yuan,et al.Phenotypic and Genotypic Characterization of Human Immunodeficiency Virus Type 1 CRF07_BC Circulating in China unpublished data
23.邢辉 梁浩 洪坤学 等 我国HIV-1主要流行株外膜蛋白(env)基因V3-V4区变异及其与生物学特性的关系 中华微生物学和免疫学杂志2005 25(3):185-189
24.Guo,Y.F.,L.Y.Ma,L.Yuan,S.H.Wang,J.P.Sun,W.S.Xu,J.Q.Xu,H.Xing,K.X.Ong,X.Y.Zhang,Y.H.Ruan,Y.X.Zhang,and Y.M.Shao.2007.R5 to X4coreceptor switch of human immunodeficiency virus type 1 B' and B'/C recombinant subtype isolates in China.Chin Med J(Engl) 120:522-5
25.Kimura,T.,K.Yoshimura,K.Nishihara,Y.Maeda,S.Matsumi,A.Koito,and S. Matsushita.2002.Reconstitution of spontaneous neutralizing antibody response against autologous human immunodeficiency virus during highly active antiretroviral therapy.J Infect Dis 185:53-60.
26.Binley,J.M.,A.Trkola,T.Ketas,D.Schiller,B.Clas,S.Little,D.Richman,A.Hurley,M.Markowitz,and J.P.Moore.2000.The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection.J Infect Dis 182:945-9
27.Kim,J.H.,J.R.Mascola,S.Ratto-Kim,T.C.VanCott,L.Loomis-Price,J.H.Cox,N.L.Michael,L.Jagodzinski,C.Hawkes,D.Mayers,B.L.Gilliam,D.C.Birx,and M.L.Robb.2001.Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged,successful drug therapy of HIV infection.AIDS Res Hum Retroviruses 17:1021-34
28.Pastori,C,C.Barassi,F.Lillo,R.Longhi,B.Capiluppi,S.Nozza,A.Galli,C.Uberti-Foppa,A.Lazzarin,G.Tambussi,and L.Lopalco.2002.The effect of HAART on humoral immune response in primary HIV-1 infected patients.J Biol Regul Homeost Agents 16:9-17
29.Koch,M.,M.Pancera,P.D.Kwong,P.Kolchinsky,C.Grundner,L.Wang,W.A.Hendrickson,J.Sodroski,and R.Wyatt.2003.Structure-based,targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.Virology 313:387-400.
30.Burton,D.R.,R.L.Stanfield,and I.A.Wilson.2005.Antibody vs.HIV in a clash of evolutionary titans.Proc Natl Acad Sci U S A 102:14943-8.
31.Kwong,P.D.,M.L.Doyle,D.J.Casper,C.Cicala,S.A.Leavitt,S.Majeed,T.D.Steenbeke,M.Venturi,I.Chaiken,M.Fung,H.Katinger,P.W.Parren,J.Robinson,D.Van Ryk,L.Wang,D.R.Burton,E.Freire,R.Wyatt,J.Sodroski,W.A.Hendrickson,and J.Arthos.2002.HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.Nature 420:678-82.
32.Berger,E.A.,Doms,R.W.,Fenyo,E.M.,Korber,B.T.,Littman,D.R.,Moore,J.P.,Sattentau,Q.J.,Schuitemaker,H.,Sodroski,J.,Weiss,R.A.A new classification for HIV-1.Nature,.1998;391,240
33.Koot M,Keet IP,Vos AH,et al.Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS.Ann Intern Med 1993;118:681-88.
34.Connor RI,Sheridan KE,Ceradini D,Choe S,Landau NR.Change in coreceptor use coreceptor use correlates with disease progression in HIV-1—infected individuals.J Exp Med 1997;185:621-28.
35.Hartley,O.,P.J.Klasse,Q.J.Sattentau,and J.P.Moore.2005.V3:HIV's switch-hitter.AIDS Res Hum Retroviruses 21:171-89.
36.Nabatov,A.A.,G.Pollakis,T.Linnemann,A.Kliphius,M.I.Chalaby,and W.A. Paxton.2004.Intrapatient alterations in the human immunodeficiency virus type 1 gp120 VIV2 and V3 regions differentially modulate coreceptor usage,virus inhibition by CC/CXC chemokines,soluble CD4,and the b12 and 2G12 monoclonal antibodies.J Virol 78:524-30.
37.Huang,C.C,M.Tang,M.Y.Zhang,S.Majeed,E.Montabana,R.L.Stanfield,D.S.Dimitrov,B.Korber,J.Sodroski,I.A.Wilson,R.Wyatt,and P.D.Kwong.2005.Structure of a V3-containing HIV-1 gp120 core.Science 310:1025-8.
38.Kang S.,Kliphuis A.,Chalaby M.I.,Goudsmit J.,Paxton W.A.N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization.(2001)J Biol Chem.276,13433-13441
39.Piatt,E.J.,Wehrly,K.,Kuhmann,S.E.,Chesebro,B.and Kabat,D.(1998)Effects of CCR5 and CD4 cell surface concentrations on infection by macrophage tropic isolates of human immunodeficiency virus type 1.J.Virol.72,2855-2864.
40.Wei,X.,Decker,J.M.,Liu,H.,Zhang,Z.,Arani,R.B.,Kilby,J.M.,Saag,M.S.,Wu,X.,Shaw,G.M.and Kappes,J.C.(2002)Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20)monotherapy.Antimicrob.Agents Chemother.46,1896-1905.
41.Harouse JM,Buckner C,Gettie A,et al.CD8+ T cell-mediated CXC chemokine receptor 4-simian human immunodeficiency virus suppression in dually infected rhesus macaques.PNAS,2003,100:10977-10982.
42.Hollinger FB,Bremer JW,Myers LE,et al.Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group.The NIH/NIAID/DAIDS/ACTG Virology Laboratories.J.Clin.Microbiol.,1992;30(7):1787-1794.
43.Quinnan,G.V,P.F.Zhang,D.W.Fu,M.Dong,and J.B.Margolick.1998.Evolution of neutralizing antibody response against HIV type 1 virions and pseudovirions in multicenter AIDS cohort study participants.AIDS Res.Hum.Retrovir.14:939-949.
44.Montefiori,D.C.(2004)Evaluating neutralizing antibodies against HIV,SIV and SHIV in luciferase reporter gene assays.Current Protocols in Immunology,(Coligan,J.E.,A.M.Kruisbeek,D.H.Margulies,E.M.Shevach,W.Strober,and R.Coico,eds.),John Wiley & Sons,12.11.1-12.11.15.
45.Synthesis and anti-HIV-1 activity of 4-[4-(4,6-bisphenylamino-[1,3,5]triazin-2-ylamino)-5-methoxy-2-methylphenylazo]-5-hydroxynaphthalene-2,7-disulfonic acid and its derivatives Kannan P.Bioorganic & Medicinal Chemistry 12 (2004)1215-1220
46.Vodros D,Tscherning-Casper C,Navea L,Schols D,De Clercq E,Fenyo EM.Quantitative evaluation of HIV-1 coreceptor use in the GHOST3 cell assay.Virology.2001 Dec5;291(1):1-11
47.Sherry M.Owen,Donna Rudolph,Dominique Schols,Nobutaka Fujii,Naoki Yamamoto,and Renu B.Lall Susceptibility of Diverse Primary HIV Isolates With Varying Co-Receptor Specificity's to CXCR4 Antagonistic Compounds.Journal of Medical Virology,2002;68:147-155
48.邵一鸣,Horal P.中国及国外某些地区HIV感染者血清HIV1 gp120 V3肽反应的研究 中华微生物学和免疫学杂志1993;13(1):1-5
49.Li,M.,F.Gao,J.R.Mascola,L.Stamatatos,V.R.Polonis,M.Koutsoukos,G.Voss,P.Goepfert,P.Gilbert,K.M.Greene,M.Bilska,D.L.Kothe,J.F.Salazar-Gonzalez,X.Wei,J.M.Decker,B.H.Hahn,and D.C.Montefiori.2005.Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.J Virol 79:10108-25
50.Li,M.,J.F.Salazar-Gonzalez,C.A.Derdeyn,L.Morris,C.Williamson,J.E.Robinson,J.M.Decker,Y.Li,M.G.Salazar,V.R.Polonis,K.Mlisana,S.A.Karim,K.Hong,K.M.Greene,M.Bilska,J.Zhou,S.Allen,E.Chomba,J.Mulenga,C.Vwalika,F.Gao,M.Zhang,B.T.Korber,E.Hunter,B.H.Hahn,and D.C.Montefiori.2006.Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.J Virol 80:11776-90
51.Crooks GE,Hon G,Chandonia JM,Brenner SE(2004) WebLogo:a sequence logo generator.Genome Res 14:1188-1190
52.Schonning,K.,B.Jansson,S.Olofsson,and J.E.Hansen.1996.Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3loop of human immunodeficiency virus type 1.J Gen Virol 77(Pt 4):753-8.
53.Malenbaum,S.E.,D.YANG,and L.CAVACINI.2000.The N-Terminal V3 Loop Glycan Modulates the Interaction of Clade A and B Human Immunodeficiency Virus Type 1 Envelopes with CD4 and Chemokine Receptors.J Virol 74:11008-11016.
54.Ogert,R.A.,M.K.Lee,W.Ross,A.Buckler-White,M.A.Martin,and M.W.Cho.2001.N-linked glycosylation sites adjacent to and within the V1/V2 and the V3loops of dualtropic human immunodeficiency virus type 1 isolate DH 12 gp 120 affect coreceptor usage and cellular tropism.J Virol 75:5998-6006.
55.ShaoYM,ZhaoF,YangWZ,etal.The identification of recombinant HIV-1 strains in IDUs in southwest and northwest China.ChinJ Labandclinvirus,1999,13:109-112
56.Moore,J.P.,L.C.Burkly,R.I.Connor,Y,Cao,R.Tizard,D.D.Ho,and R.A.Fisher.1993.Adaptation of two primary human immunodeficiency virus type 1isolates to growth in transformed T cell lines correlates with alterations in the response of their envelope glycoproteins to soluble CD4.AIDS Res.Hum.Retrovir.9:529-539
57.Willey,R.L.,M.A.Martin,and K.W.C.Peden.1994.Increase in soluble CD4binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1.J.Virol.68:1029-1039.
58.Parren,P.W.,1998.Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1.J.Virol.72:10270-10274
59.Trkola,A.,H.Kuster,and P.Rusert.2008.In Vivo Efficacy of Human Immunodeficiency Virus Neutralizing Antibodies:Estimates for Protective Titers.J Virol 82:1591-1599.
60.Li,B.,J.M.Decker,R.W.Johnson,F.Bibollet-Ruche,X.Wei,J.Mulenga,S.Allen,E.Hunter,B.H.Hahn,G.M.Shaw,J.L.Blackwell,and C.A.Derdeyn.2006.Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1.J Virol 80:5211-8.
61.Wang,Q.,H.Shang,X.Han,Z.Zhang,Y.Jiang,Y.Wang,D.Dai,and Y.Diao.2008.High level serum neutralizing antibody against HIV-1 in Chinese long-term non-progressors.Microbiol Immunol 52:209-15.
62.Albert,J.,B.Abrahamsson,K.Nagy,E.Aurelius,H.Gaines,G.Nystrom,and E.M.Fenyo.1990.Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.Aids 4:107-12.
63.K Schonning,M Joost,GJ Gram,R Machuca,C Nielsen,JO Nielsen,and JE Hansen.Chemokine receptor polymorphism and autologous neutralizing antibody response in long-term HIV-1 infection.J Acquir Immune Defic Syndr Hum Retrovirol,1998;18(3):195-202.
64.Deeks,S.G,B.Schweighardt,T.Wrin,J.Galovich,R.Hoh,E.Sinclair,P.Hunt,J.M.McCune,J.N.Martin,C.J.Petropoulos,and F.M.Hecht.2006.Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV)infection:evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses.J Virol 80:6155-64
65.V Bongertz,CI Costa,VG Santos,EC Joao Filho,B Galvao-Castro,and MG Morgado.Correlation between susceptibility of primary HIV-1 isolates to autologous and heterologous neutralizing antibodies.Hospital Evandro Chagas AIDS Clinical Research Group.AIDS,1997;11(8):969-75.
66.Warren,R.Q.,S.A.Anderson,W.M.Nkya,J.F.Shao,C.W.Hendrix,G P.Melcher,R.R.Redfield,and R.C.Kennedy.1992.Examination of sera from human immunodeficiency virus type 1 (HlV-l)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.J Virol 66:5210-5
67.Ugolini,B.S.,I.Mondor,and P.W.H.I.Parren.1997.Inhibition of Virus Attachment to CD4 Target Cells Is a Major Mechanism of T Cell Line-adapted HIV-1 Neutralization.J.Exp.Med.:1287-1298.
68.Schonning,K.,O.Lund,O.S.Lund,and J.E.Hansen.1999.Stoichiometry of monoclonal antibody neutralization of T-cell line-adapted human immunodeficiency virus type 1.J Virol 73:8364-70.
69.Salzwedel,K.,J.T.West,and E.Hunter.1999.A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity.J Virol 73:2469-80.
70.Binley,J.,and J.P.Moore.1997.HlV-cell fusion.The viral mousetrap.Nature 387:346-8.
71.Ahmad A,Menezes J:Antibody-dependent cellular cytotoxicity in HIV infections.FASEBJ1996,10:258-266.
72.Ahmad R,Sindhu ST,Toma E,Morisset R,Vincelette J,Menezes J,Ahmad A:Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection.J Clin Immunol 2001,21:227-233.
73.Holl V,Peressin M,Decoville T,Schmidt S,Zolla-Pazner S,et al.Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells.J Virol,2006;80:6177-6181.
74.Hessell AJ,Hangartner L,Hunter M,HavenithCEG,Beurskens FJ,et al.Fc receptorbut not complement binding is important in antibody protection against HIV.Nature.2007;449:101-105.
75.Duval,M.,M.R.Posner,and L.A.Cavacini.2008.A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils.J Virol 82:4671-4
76.Edward Robinson,David C.Montefiori,William M.Mitchell,Alfred M.Prince,Harvey J.Alter,Gordon R.Dreesman,and Jorg W.Eichberg.Antibody-Dependent Enhancement of Human Immunodeficiency Virus Type 1 (HIV-1)Infection in vitro by Serum from HIV-1-Infected and Passively Immunized ChimpanzeesW.PNAS,1989;86:4710-4714
77.gamma R.A Takeda,R W Sweet,and F A Ennis.Two receptors are required for antibody-dependent enhancement of human immunodeficiency virus type 1 infection:CD4 and Fc J.Virol.,1990;64:5605-5610.
78.WE Robinson Jr,DC Montefiori,and WM Mitchell.Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors.Virology,1990;175(2):600-4.
79.Weber,J.,E.M.Fenyo,S.Beddows,P.Kaleebu,and A.Bjorndal.Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype.The WHO Network for HIV Isolation and Characterization.J Virol 1996.70:7827-32.
80.Chong,H.,K.Hong,C.Zhang,J.Nie,A.Song,W.Kong,and Y.Wang.2008.Genetic and Neutralization Properties of HIV-1 env Clones From Subtype B/BC/AE Infections in China.J Acquir Immune Defic Syndr 47:535-543.
81.Binley,J.M.,T.Wrin,and B.Korber.2004.Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1Monoclonal Antibodies.J Virol 78:13232-13252.
82.Derdeyn,C.A.,J.M.Decker,F.Bibollet-Ruche,J.L.Mokili,M.Muldoon,S.A.Denham,M.L.Heil,F.Kasolo,R.Musonda,B.H.Hahn,G.M.Shaw,B.T.Korber,S.Allen,and E.Hunter.2004.Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.Science 303:2019-22
83.Sagar,M.,X.Wu,S.Lee,and J.Overbaugh.2006.Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection,and these modifications affect antibody neutralization sensitivity.J Virol 80:9586-98.
84.Koch,M.,M.Pancera,P.D.Kwong,P.Kolchinsky,C.Grundner,L.Wang,W.A.Hendrickson,J.Sodroski,and R.Wyatt.2003.Structure-based,targeted deglycosylation of HIV-1 gp 120 and effects on neutralization sensitivity and antibody recognition.Virology 313:387-400.
85.Wei,X.,J.M.Decker,S.Wang,H.Hui,J.C.Kappes,X.Wu,J.F.Salazar-Gonzalez,M.G.Salazar,J.M.Kilby,M.S.Saag,N.L.Komarova,M.A.Nowak,B.H.Hahn,P.D.Kwong,and G.M.Shaw.2003.Antibody neutralization and escape by HIV-1.Nature 422:307-12.
86.Liu,S.,H.Xing,X.He,R.Xin,Y.Zhang,J.Zhu,and Y.Shao.2008.Analysis of Putative N-Linked Glycosylation Sites and Variable Region of Envelope HIV-1CRF07_BC Recombinant in Intravenous Drug Users in Xinjiang Autonomous Region,China.AIDS Res Hum Retroviruses 24:521-527.
87.Cham,F.,P.F.Zhang,L.Heyndrickx,P.Bouma,P.Zhong,H.Katinger,J.Robinson,G.van der Groen,and G.V.Quinnan,Jr.2006.Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.Virology 347:36-51.
88.Jensen,M.A.,F.S.Li,A.B.van't Wout,D.C.Nickle,D.Shriner,H.X.He,S.McLaughlin,R.Shankarappa,J.B.Margolick,and J.I.Mullins.2003.Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences.J Virol 77:13376-88
89.赵全璧 潘品良 温宁 等 中国艾滋病病毒1型流行毒株V3环序列变异性的研究 中国性病艾滋病防治2002,8(4):208-211
90.Ndung'u,T.,E.Sepako,M.F.McLane,F.Chand,K.Bedi,S.Gaseitsiwe,F.Doualla-Bell,T.Peter,I.Thior,S.M.Moyo,P.B.Gilbert,V.A.Novitsky,and M.Essex.2006.HIV-1 subtype C in vitro growth and coreceptor utilization.Virology 347:247-60.
91.Patel,M.B.,N.G.Hoffman,and R.Swanstrom.2008.Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins.J Virol 82:903-16.
92.Lusso,P.,P.L.Earl,F.Sironi,F.Santoro,C.Ripamonti,G.Scarlatti,R.Longhi,E.A.Berger,and S.E.Burastero.2005.Cryptic nature of a conserved,CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted,but not CXCR4-using,primary human immunodeficiency virus type 1 strains.J Virol 79:6957-68
93.Bunnik,E.M.,E.D.Quakkelaar,A.C.v.Nuenen,B.Boeser-Nunnink,and H.Schuitemaker.2007.Increased Neutralization Sensitivity of Recently Emerged CXCR4-Using Human Immunodeficiency Virus Type 1 Strains Compared to Coexisting CCR5-Using Variants from the Same Patient.J Virol:525-531
94.Cecilia,D.,V.N.KewalRamani,J.O'Leary,B.Volsky,P.Nyambi,S.Burda,S.Xu,D.R.Littman,and S.Zolla-Pazner.1998.Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage.J Virol 72:6988-96
95.Morris,M.K.,D.A.Katzenstein,D.Israelski,A.Zolopa,R.M.Hendry,and C.V.Hanson.2001.Characterization of the HIV-1 specific humoral immune response during highly active antiretroviral therapy (HAART).J Acquir Immune Defic Syndr 28:405-15
96.Bongertz,V,E.P.Ouverney,S.C.Fernandez,B.Grinsztejn,V.Veloso,J.C.Couto-Fernandez,J.H.Pilotto,and M.G Morgado.2007.Anti-human immunodeficiency virus type 1 humoral immune response and highly active antiretroviral treatment.Mem Inst Oswaldo Cruz 102:817-25.
1.Capon DJ,Ward RH.The CD4-gp120 interaction and AIDS pathogenesis.Annu Rev Immunol 1991;9:649-678
2.Bernstein HB,Tucker SP,Kar SR,et.al.Oligomerization of the hydrophobic heptad repeat of gp41.J Virol 1995;69:2745-2750.
3.Moore,J.P.,and J.Sodroski.1996.Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp 120 exterior envelope glycoprotein.J Virol 70:1863-72.
4.Kwong PD,Wyatt R,Robinson J.Structure of an HIV gp 120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.Nature.1998;393:648-59
5.Koch,M.,M.Pancera,P.D.Kwong,P.Kolchinsky,C.Grundner,L.Wang,W.A.Hendrickson,J.Sodroski,and R.Wyatt.2003.Structure-based,targeted deglycosylation of HIV-1 gp 120 and effects on neutralization sensitivity and antibody recognition.Virology 313:387-400.
6.Burton,D.R.,R.L.Stanfield,and I.A.Wilson.2005.Antibody vs.HIV in a clash of evolutionary titans.Proc Natl Acad Sci U S A 102:14943-8.
7.Kwong,P.D.,M.L.Doyle,D.J.Casper,C.Cicala,S.A.Leavitt,S.Majeed,T.D. Steenbeke,M.Venturi,I.Chaiken,M.Fung,H.Katinger,P.W.Parren,J.Robinson,D.Van Ryk,L.Wang,D.R.Burton,E.Freire,R.Wyatt,J.Sodroski,W.A.Hendrickson,and J.Arthos.2002.HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.Nature 420:678-82.
8.Krachmarov,C.P.,W.J.Honnen,S.C.Kayman,M.K.Gorny,S.Zolla-Pazner,and A.Pinter.2006.Factors Determining the Breadth and Potency of Neutralization by V3-Specific Human Monoclonal Antibodies Derived from Subjects Infected with Clade A or Clade B Strains of Human Immunodeficiency Virus Type 1.J Virol 80:7127-7135
9.Cao,J.,N.Sullivan,E.Desjardin,C.Parolin,J.Robinson,R.Wyatt,and J.Sodroski.1997.Replication and neutralization of human immunodeficiency virus type 1 lacking the VI and V2 variable loops of the gp120 envelope glycoprotein.J Virol 71:9808-12.
10.STAMATATOS,L.,and C.CHENG-MAYER.1998.An Envelope Modification That Renders a Primary,Neutralization-Resistant Clade B Human Immunodeficiency Virus Type 1 Isolate Highly Susceptible to Neutralization by Sera from Other Clades.J Virol 72:7840-7845.
11.Rong,R.,F.Bibollet-Ruche,J.Mulenga,S.Allen,J.L.Blackwell,and C.A.Derdeyn.2007.Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection.J Virol 81:1350-9
12.Lue,J.,M.Hsu,D.Yang,P.Marx,Z.Chen,and C.Cheng-Mayer.2002.Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1.J Virol 76:10299-306.
13.Ching,L.K.,G.Vlachogiannis,K.A.Bosch,and L.Stamatatos.2008.The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen.J Virol 82:949-56.
14.Li,Y,B.Cleveland,I.Klots,B.Travis,B.A.Richardson,D.Anderson,D.Montefiori,P.Polacino,and S.L.Hu.2008.Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses.J Virol 82:638-51
15.Beaumont,T.,E.Quakkelaar,A.van Nuenen,R.Pantophlet,and H.Schuitemaker.2004.Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus ⅢB strain isolated from an accidentally infected laboratory worker.J Virol 78:5651-7
16.Wolk,T.,and M.Schreiber.2006.N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization.Med Microbiol Immunol 195:165-72
17.Broliden,P.A.,B.Makitalo,L.Akerblom,J.Rosen,K.Broliden,G.Utter,M.Jondal,E.Norrby,and B.Wahren.1991.Identification of amino acids in the V3 region of gp120 critical for virus neutralization by human HIV-1-specific antibodies.Immunology 73:371-6
18.Spear,G.T.,D.M.Takefman,S.Sharpe,M.Ghassemi,and S.Zolla-Pazner.1994.Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation,antibody binding,and neutralization.Virology 204:609-15.
19.Kim,Y.B.,D.P.Han,C.Cao,and M.W.Cho.2003.Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies.Virology 305:124-37.
20.Bell,C.H.,R.Pantophlet,A.Schiefner,L.A.Cavacini,R.L.Stanfield,D.R.Burton,and I.A.Wilson.2008.Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization.J Mol Biol 375:969-78
21.Malenbaum,S.E.,D.YANG,and L.CAVACINI.2000.The N-Terminal V3 Loop Glycan Modulates the Interaction of Clade A and B Human Immunodeficiency Virus Type 1 Envelopes with CD4 and Chemokine Receptors.J Virol 74:11008-11016.
22.McCaffrey,R.A.,C.Saunders,M.Hensel,and L.Stamatatos.2004.N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.J Virol 78:3279-95.
23.Liang,H.,M.Wei,Z.Chen,H.Xing,Q.B.Zhao,Y.Feng,Q.Guan,L.Y.Shi,and Y.M.Shao.2003.[Sequence variation in the env V3-V4 region of HIV type 1 predominant subtype B and C strains circulating in China].Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 17:153-8.
24.Liang,H.,H.Xing,J.Z.Li,M.Wei,K.X.Hong,Y.Feng,Q.B.Zhao,J.P.Chen,Y.Quan,T.Teng,and Y M.Shao.2005.[Identification of signature amino acids in the env V3-V4 and flanking regions of human immunodeficiency virus type 1 predominant strains in China].Zhonghua Yi Xue Za Zhi 85:897-902.
25.Moore,P.L.,E.S.Gray,and I.A.Choge.2008.The C3-V4 Region Is a Major Target of Autologous Neutralizing Antibodies in Human Immunodeficiency Virus Type 1 Subtype C Infection.J Virol 82:1860-1869.
26.Castro,E.,M.Belair,G.P.Rizzardi,P.A.Bart,G.Pantaleo,and C.Graziosi.2008.Independent evolution of hypervariable regions of HIV-1 gp120:V4 as a swarm of N-Linked glycosylation variants.AIDS Res Hum Retroviruses 24:106-13.
27.Sanders,R.W,E.van Anken,A.A.Nabatov,I.M.Liscaljet,I.Bontjer,D.Eggink,M.Melchers,E.Busser,M.M.Dankers,F.Groot,I.Braakman,B.Berkhout,and W.A.Paxton.2008.The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion.Retrovirology 5:10.
28.Gnanakaran,S.,D.Lang,M.Daniels,T.Bhattacharya,C.A.Derdeyn,and B.Korber.2007.Clade-specific differences between human immunodeficiency virus type 1 clades B and C:diversity and correlations in C3-V4 regions of gp120.J Virol 81:4886-91.
29.Harrington,P.R.,J.A.E.Nelson,K.M.Kitrinos,and R.Swanstrom.2007.Independent Evolution of Human Immunodeficiency Virus Type 1 env V1/V2 and V4/V5 Hypervariable Regions during Chronic Infection.J Virol 81:5413-5417.
30.Nygren,A.,T.Bergman,T.Matthews,H.Jornvall,and H.Wigzell.1988.95-and 25-kDa fragments of the human immunodeficiency virus envelope glycoprotein gp120 bind to the CD4 receptor.Proc Natl Acad Sci U S A 85:6543-6.
31.Chan,S.Y.,R.F.Speck,C.Power,S.L.Gaffen,B.Chesebro,and M.A.Goldsmith.1999.V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1.J Virol 73:2350-8.
32.Pastore,C,R.Nedellec,A.Ramos,S.Pontow,L.Ratner,and D.E.Mosier.2006.Human immunodeficiency virus type 1 coreceptor switching:V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.J Virol 80:750-8.
33.Kiselyeva,Y,R.Nedellec,A.Ramos,C.Pastore,L.B.Margolis,and D.E.Mosier.2007.Evolution of CXCR4-using human immunodeficiency virus type 1 SF162 is associated with two unique envelope mutations.J Virol 81:3657-61
34.Wyatt,R.,N.Sullivan,M.Thali,H.Repke,D.Ho,J.Robinson,M.Posner,and J.Sodroski.1993.Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions.J Virol 67:4557-65
35.Wyatt,R.,J.Moore,M.Accola,E.Desjardin,J.Robinson,and J.Sodroski.1995.Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.J Virol 69:5723-33
36.Feng,Y,C.C.Broder,P.E.Kennedy,and E.A.Berger.1996.HIV-1 entry cofactor:functional cDNA cloning of a seven-transmembrane,G protein-coupled receptor.Science 272:872-7.
37.Deng,H.,R.Liu,W.Ellmeier,S.Choe,D.Unutmaz,M.Burkhart,P.Di Marzio,S.Marmon,R.E.Sutton,C.M.Hill,C.B.Davis,S.C.Peiper,T.J.Schall,D.R.Littman,and N.R.Landau.1996.Identification of a major co-receptor for primary isolates of HIV-1.Nature 381:661-6.
38.Dragic,T.,V.Litwin,G.P.Allaway,S.R.Martin,Y.Huang,K.A.Nagashima,C.Cayanan,P.J.Maddon,R.A.Koup,J.P.Moore,and W.A.Paxton.1996.HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.Nature 381:667-73.
39.Berger,E.A.,R.W.Doms,E.M.Fenyo,B.T.Korber,D.R.Liftman,J.P.Moore,Q.J.Sattentau,H.Schuitemaker,J.Sodroski,and R.A.Weiss.1998.A new classification for HIV-1.Nature 391:240.
40.Alkhatib,G,C.Combadiere,C.C.Broder,Y.Feng,P.E.Kennedy,P.M.Murphy,and E.A.Berger.1996.CC CKR5:a RANTES,MIP-1 alpha,MlP-lbeta receptor as a fusion cofactor for macrophage-tropic HIV-1.Science 272:1955-8
41.Cilliers,T.,and L.Morris.2002.Coreceptor usage and biological phenotypes of HIV-1 isolates.Clin Chem Lab Med 40:911-7.
42.Hartley,O.,P.J.Klasse,Q.J.Sattentau,and J.P.Moore.2005.V3:HIV's switch-hitter.AIDS Res Hum Retroviruses 21:171-89.
43.Nabatov,A.A.,G.Pollakis,T.Linnemann,A.Kliphius,M.I.Chalaby,and W.A.Paxton.2004.Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage,virus inhibition by CC/CXC chemokines,soluble CD4,and the b 12 and 2G12 monoclonal antibodies.J Virol 78:524-30.
44.Hwang,S.S.,T.J.Boyle,H.K.Lyerly,and B.R.Cullen.1991.Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1.Science 253:71-4
45.Garrido,C,V.Roulet,N.Chueca,E.Poveda,A.Aguilera,K.Skrabal,N.Zahonero,S.Carlos,F.Garcia,J.L.Faudon,V Soriano,and C.de Mendoza.2008.Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes.J Clin Microbiol 46:887-91.
46.Jensen,M.A.,and A.B.van 't Wout.2003.Predicting HIV-1 coreceptor usage with sequence analysis.AIDS Rev,5:104-12.
47.Saracino,A.,L.Monno,G Punzi,D.C.Cibelli,A.Tartaglia,L.Scudeller,G.Brindicci,A.Lagioia,G Scotto,and G Angarano.2007.HIV-1 biological phenotype and predicted coreceptor usage based on V3 loop sequence in paired PBMC and plasma samples.Virus Res 130:34-42.
48.Kato,K.,H.Sato,and Y.Takebe.1999.Role of naturally occurring basic amino acid substitutions in the human immunodeficiency virus type 1 subtype E envelope V3 loop on viral coreceptor usage and cell tropism.J Virol 73:5520-6.
49.Jensen,M.A.,F.S.Li,A.B.van 't Wout,D.C.Nickle,D.Shriner,H.X.He,S.McLaughlin,R.Shankarappa,J.B.Margolick,and J.I.Mullins.2003.Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences.J Virol 77:13376-88.
50.Rosen,O.,A.O.Samson,and J.Anglister.2008.Correlated mutations at gp120 positions 322 and 440:Implications for gp120 structure.Proteins 71:1066-1070
51.Geijtenbeek,T.B.,D.S.Kwon,R.Torensma,S.J.van Vliet,G.C.van Duijnhoven,J.Middel,I.L.Cornelissen,H.S.Nottet,V.N.KewalRamani,D.R.Littman,C.G.Figdor,and Y.van Kooyk.2000.DC-SIGN,a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells.Cell 100:587-97.
52.Chan,D.C,D.Fass,J.M.Berger,and P.S.Kim.1997.Core structure of gp41 from the HIV envelope glycoprotein.Cell 89:263-73.
53.Zwick,M.B.,R.Jensen,S.Church,M.Wang,G.Stiegler,R.Kunert,H.Katinger,and D.R.Burton.2005.Anti-human immunodeficiency virus type 1 (HIV-1)antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.J Virol 79:1252-61.
54.Park,E.J.,M.K.Gorny,S.Zolla-Pazner,and G.V.Quinnan,Jr.2000.A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.J Virol 74:4183-91
55.Watkins,B.A.,S.Buge,K.Aldrich,A.E.Davis,J.Robinson,M.S.Reitz,Jr.,and M.Robert-Guroff.1996.Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites.J Virol 70:8431-7.
56.Kalia,V,S.Sarkar,P.Gupta,and R.C.Montelaro.2005.Antibody neutralization escape mediated by point mutations in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41.J Virol 79:2097-107.
57.Blish,C.A.,M.A.Nguyen,and J.Overbaugh.2008.Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41.PLoS Med 5:e9.
58.Montero,M.,N.E.van Houten,X.Wang,and J.K.Scott.2008.The membrane-proximal external region of the human immunodeficiency virus type 1 envelope:dominant site of antibody neutralization and target for vaccine design.Microbiol Mol Biol Rev 72:54-84
59.Gray,E.S.,P.L.Moore,F.Bibollet-Ruche,H.Li,J.M.Decker,T.Meyers,G.M.Shaw,and L.Morris.2008.4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response.J Virol 82:2367-75.
60.Pikora,C.A.2004.Glycosylation of the ENV spike of primate immunodeficiency viruses and antibody neutralization.Curr HIV Res 2:243-54.
61.Wyatt R.,Sodroski J.The HIV-1 envelope glycoproteins:fusogens,antigens,and immunogens.Science 1998;280 (5371):1884-1888.
62.Wei,X.,J.M.Decker,S.Wang,H.Hui,J.C.Kappes,X.Wu,J.F.Salazar-Gonzalez,M.G Salazar,J.M.Kilby,M.S.Saag,N.L.Komarova,M.A.Nowak,B.H.Hahn,P.D.Kwong,and G.M.Shaw.2003.Antibody neutralization and escape by HIV-1.Nature 422:307-12.
63.Ogert,R.A.,M.K.Lee,W.Ross,A.Buckler-White,M.A.Martin,and M.W.Cho.2001.N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dual tropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism.J Virol 75:5998-6006.
64.Reynard,F.,A.Fatmi,B.Verrier,and F.Bedin.2004.HIV-1 acute infection env glycomutants designed from 3D model:effects on processing,antigenicity,and neutralization sensitivity.Virology 324:90-102.
65.Li,H.,P.C.Chien,Jr.,M.Tuen,M.L.Visciano,S.Cohen,S.Blais,C.F.Xu,H.T.Zhang,and C.E.Hioe.2008.Identification of an N-linked glycosylation in the C4 region of HIV-1 envelope gp120 that is critical for recognition of neighboring CD4 T cell epitopes.J Immunol 180:4011-21.
1.Moore JP and Stevenson M.New targets for inhibitors of HIV-1 replication[J].Nat Rev Mol Cell Biol,2000;1(1):40-49.
2.Fletcher CV.Enfuvirtide,a new drug for HIV infection[J].Lancet,2003;361(9369):1577-1578.
3.Wu Hao,Myszka DG,Tendian SW,et al.Kinetic and structural analysis of mutant CD4 receptors that are defective in HIVgpl20binding[J].Proc Natl Acad Sci USA,1996;93:15030-15035.
4.MadaniN,PerdigotoAL,Srinivasan K,et al.Localized Changes in the gp120Envelope Glycoprotein Confer Resistance to Human Immunodeficiency Virus Entry Inhibitors BMS-806 and #155[J].J.Virol,2004;78:3742-3752.
5.Jacobson JM,Lowy I,Fletcher CV,et al.Single-dose safety,pharmacology,and antiviral activity of the human immunodeficiency virus(HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults[J].J Infect Dis,2000;182(1):326-329.
6.Moore PL,Cilliers T,Morris L.Predicted genotypic resistance to the novel entry inhibitor,BMS-378806,among HIV-1 isolates of subtypes A to G[J].AIDS,2004;18(17):2327-2330..
7.Schols D.HIV co-receptor inhibitors as novel class of anti-HIV drugs[J].Antiviral Res,2006;71(2-3):216-226.
8.FDA Approval:Maraviroc AIDS Clinical Care,2007;2007:1.
9.Trkola A,Ketas TJ,Nagashima KA,et al.Potent,broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140[J].J.Virol,2001,75(2):579-588.
10.Dragic T,Trkola A,Thompson D.et al.A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5[J].Proc Natl Acad Sci USA,2000;97:5639-5644.
11.Trkola A,Kuhmann SE,Strizki JM,et al.HIV-1 escape from a small molecule,CCR5-specific entry inhibitor does not involve CXCR4use[J].PNAS,2002;99:395-400.
12.Maeda Y,Foda M,Matsushita S,et al.Involvement of both the V2 and V3 Regions of the CCR5-Tropic Human Immunodeficiency Virus Type 1 Envelope in Reduced Sensitivity to Macrophage Inflammatory Protein 1α[J].J.Virol.,2000;74:1787-1793.
13.Mosier DE,Picchio GR,Gulizia RJ,et al.Highly Potent RANTES Analogues either Prevent CCR5-Using Human Immunodeficiency Virus Type 1 Infection In Vivo or Rapidly Select for CXCR4-Using Variants[J].J.Virol,1999;73:3544-3550.
14 Westby M,Smith-Burchnell C,Mori J,et al.Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry J.Virol.,2007;81:2359-2371.
15.Schols D,.Este JA,Cabrera C,et al.T-Cell-Line-Tropic Human Immunodeficiency Virus Type 1 That Is Made Resistant to Stromal Cell-Derived Factor la Contains Mutations in the Envelope gp120 but Does Not Show a Switch in CoreceptorUse [J].J.Virol.,1998;72:4032-4037.
16.Vreese K,Kofler-Mongold V,Leutgeb C,et al.The molecular target of bicyclams,potent inhibitors of human immunodeficiency virus replication[J]J.Virol,1996;70:689-696.
17.Nolan KM,Jordan A,and.Hoxie JA.Effects of Partial Deletions within the HIV-1 V3 Loop on Coreceptor Tropism and Sensitivity to Entry Inhibitors[J]J.Virol.,2007;10.1128/JVI.01793-07
18.Welch BD,VanDemark AP,Heroux A,Potent D-peptide inhibitors of HIV-1 entry[J].Proc Natl Acad Sci,2007;43:16828-16838
19.RootMJ,KayMS,Kim PS.Protein design of an HIV-1 entry inhibitor[J].Science,2001;291(5505):884-888.
20.Munch J,StandkerL,Adermann K,Discovery and Optimization of a Natural HIV-1 Entry Inhibitor Targeting the gp41 Fusion Peptide[J].cell,2007;129:263-275
21.Sista PR,Melby T,Davison D,et al.Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates[J].AIDS,2004;18(13):1787-94.
22.Johnson VA,Brun-Vezinet F,Clotet B,et al.Update of the drug resistance mutations in HIV-1:Fall 2006[J].Top HIV Med,2006;14(3):125-30
23.Heredia A,Gilliam B,DeVico A,et al.CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1[J].AIDS,2007;21(10):1317-22.
24.Reeves J,Gallo S,Ahmad N,et al.Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity,receptor density,and fusion kinetics[J].Proc Natl Acad Sci USA,2002;99:16249-54.
25.Ray N,Harrison JE,Blackburn L,et al.Clinical Resistance to Enfuvirtide Does Not Affect Susceptibility of Human Immunodeficiency Virus Type 1 to Other Classes of Entry Inhibitors[J].J.Virol,2007;81:3240-3250.
2.Paul,W.E.1995.Can the immune response control HIV infection? Cell 82:177-82.
3.Pilgrim,A.K.,G.Pantaleo,O.J.Cohen,L.M.Fink,J.Y.Zhou,J.T.Zhou,D.P.Bolognesi,A.S.Fauci,and D.C.Montefiori.1997.Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.J Infect Dis 176:924-32
4.Arendrup,M.,C.Nielsen,J.E.Hansen,C.Pedersen,L.Mathiesen,and J.O.Nielsen.1992.Autologous HIV-1 neutralizing antibodies:emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies.J Acquir Immune Defic Syndr 5:303-7
5.Moog,C,H.J.Fleury,I.Pellegrin,A.Kirn,and A.M.Aubertin.1997.Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.J Virol 71:3734-41.
6.Cao,Y,L.QIN,and L.ZHANG.1995.VIROLOGIC AND IMMUNOLOGIC CHARACTERIZATION OF LONG-TERM SURVIVORS OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION.THE NEW ENGLAND JOURNAL OF MEDICINE 332:201-208.
7.Harrer,T.,E.Harrer,S.A.Kalams,T.Elbeik,S.I.Staprans,M.B.Feinberg,Y.Cao,D.D.Ho,T.Yilma,A.M.Caliendo,R.P.Johnson,S.P.Buchbinder,and B.D.Walker.1996.Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection.AIDS Res Hum Retroviruses 12:585-92
8.McMichael AJ,Hanke T.HIV vaccines 1983-2003.
9.Nat Med,2003;9(7):874-880.Watanabe ME.Skeptical scientists skewer VaxGen statistics.Nat Med,2003;9(4):376
10.Rollman,E.,J.Hinkula,J.Arteaga,B.Zuber,A.Kjerrstrom,M.Liu,B.Wahren,and K.Ljungberg.2004.Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies.Gene Ther 11:1146-54
11.Ferrantelli F,Rasmussen RA,Buckley KA,Li PL,Wang T,et al.Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies.J Infect Dis.2004;189:2167-2173.
12.Mascola JR,Stiegler G,VanCott TC,Katinger H,Carpenter CB,et al.Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.Nat Med.2000;6:207-210.
13.Parren PW,Marx PA,Hessell AJ,Luckay A,Harouse J,et al.Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.J Virol.2001;75:8340-8347
14.Shibata R,Igarashi T,Haigwood N,Buckler-White A,Ogert R,et al.Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.Nat Med.1999;5:204-210.
15.Vertical HIV-1 transmission:importance of neutralizing antibody titer and specificity.V Bongertz,CI Costa,VG Veloso,Scand J Immunol,2001;53(3):302-9
16.Zwick MB,Labrijn AF,Wang M,Spenlehauer C,Saphire EO,Binley JM,Moore JP,Stiegler G,Katinger H,Burton DR et al.:Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1glycoprotein gp41.J Virol 2001,75:10892-10905.
17.Xu W,Smith-Franklin BA,Li PL,Wood C,He J,Du Q,Bhat GJ,Kankasa C,Katinger H,Cavacini LA et al.Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B.J Hum Virol 2001,4:55-61.
18.Zwick MB,Wang M,Poignard P,Stiegler G,Katinger H,Burton DR,Parren PW:Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.J Virol 2001,75:12198-12208.
19.Verrier F,Nadas A,Gorny MK,Zolla-Pazner S:Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6.J Virol 2001,75:9177-9186.
20.Shao Y.Report on the 2nd National HIV MolecularEpidemiology Survey.Basic Science Update by ChineseMinistry of Science and Technology 2004;5:16-18.
21.关琪,邢辉,邵一鸣,等.我国HIV-1 B′亚型毒株gag基因变异特征研究.第二届世界华人临床生化和检验医学大会论文汇编,2004,348-351.
22.liying Ma,Yanfang Guo,Lin Yuan,et al.Phenotypic and Genotypic Characterization of Human Immunodeficiency Virus Type 1 CRF07_BC Circulating in China unpublished data
23.邢辉 梁浩 洪坤学 等 我国HIV-1主要流行株外膜蛋白(env)基因V3-V4区变异及其与生物学特性的关系 中华微生物学和免疫学杂志2005 25(3):185-189
24.Guo,Y.F.,L.Y.Ma,L.Yuan,S.H.Wang,J.P.Sun,W.S.Xu,J.Q.Xu,H.Xing,K.X.Ong,X.Y.Zhang,Y.H.Ruan,Y.X.Zhang,and Y.M.Shao.2007.R5 to X4coreceptor switch of human immunodeficiency virus type 1 B' and B'/C recombinant subtype isolates in China.Chin Med J(Engl) 120:522-5
25.Kimura,T.,K.Yoshimura,K.Nishihara,Y.Maeda,S.Matsumi,A.Koito,and S. Matsushita.2002.Reconstitution of spontaneous neutralizing antibody response against autologous human immunodeficiency virus during highly active antiretroviral therapy.J Infect Dis 185:53-60.
26.Binley,J.M.,A.Trkola,T.Ketas,D.Schiller,B.Clas,S.Little,D.Richman,A.Hurley,M.Markowitz,and J.P.Moore.2000.The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection.J Infect Dis 182:945-9
27.Kim,J.H.,J.R.Mascola,S.Ratto-Kim,T.C.VanCott,L.Loomis-Price,J.H.Cox,N.L.Michael,L.Jagodzinski,C.Hawkes,D.Mayers,B.L.Gilliam,D.C.Birx,and M.L.Robb.2001.Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged,successful drug therapy of HIV infection.AIDS Res Hum Retroviruses 17:1021-34
28.Pastori,C,C.Barassi,F.Lillo,R.Longhi,B.Capiluppi,S.Nozza,A.Galli,C.Uberti-Foppa,A.Lazzarin,G.Tambussi,and L.Lopalco.2002.The effect of HAART on humoral immune response in primary HIV-1 infected patients.J Biol Regul Homeost Agents 16:9-17
29.Koch,M.,M.Pancera,P.D.Kwong,P.Kolchinsky,C.Grundner,L.Wang,W.A.Hendrickson,J.Sodroski,and R.Wyatt.2003.Structure-based,targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.Virology 313:387-400.
30.Burton,D.R.,R.L.Stanfield,and I.A.Wilson.2005.Antibody vs.HIV in a clash of evolutionary titans.Proc Natl Acad Sci U S A 102:14943-8.
31.Kwong,P.D.,M.L.Doyle,D.J.Casper,C.Cicala,S.A.Leavitt,S.Majeed,T.D.Steenbeke,M.Venturi,I.Chaiken,M.Fung,H.Katinger,P.W.Parren,J.Robinson,D.Van Ryk,L.Wang,D.R.Burton,E.Freire,R.Wyatt,J.Sodroski,W.A.Hendrickson,and J.Arthos.2002.HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.Nature 420:678-82.
32.Berger,E.A.,Doms,R.W.,Fenyo,E.M.,Korber,B.T.,Littman,D.R.,Moore,J.P.,Sattentau,Q.J.,Schuitemaker,H.,Sodroski,J.,Weiss,R.A.A new classification for HIV-1.Nature,.1998;391,240
33.Koot M,Keet IP,Vos AH,et al.Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS.Ann Intern Med 1993;118:681-88.
34.Connor RI,Sheridan KE,Ceradini D,Choe S,Landau NR.Change in coreceptor use coreceptor use correlates with disease progression in HIV-1—infected individuals.J Exp Med 1997;185:621-28.
35.Hartley,O.,P.J.Klasse,Q.J.Sattentau,and J.P.Moore.2005.V3:HIV's switch-hitter.AIDS Res Hum Retroviruses 21:171-89.
36.Nabatov,A.A.,G.Pollakis,T.Linnemann,A.Kliphius,M.I.Chalaby,and W.A. Paxton.2004.Intrapatient alterations in the human immunodeficiency virus type 1 gp120 VIV2 and V3 regions differentially modulate coreceptor usage,virus inhibition by CC/CXC chemokines,soluble CD4,and the b12 and 2G12 monoclonal antibodies.J Virol 78:524-30.
37.Huang,C.C,M.Tang,M.Y.Zhang,S.Majeed,E.Montabana,R.L.Stanfield,D.S.Dimitrov,B.Korber,J.Sodroski,I.A.Wilson,R.Wyatt,and P.D.Kwong.2005.Structure of a V3-containing HIV-1 gp120 core.Science 310:1025-8.
38.Kang S.,Kliphuis A.,Chalaby M.I.,Goudsmit J.,Paxton W.A.N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization.(2001)J Biol Chem.276,13433-13441
39.Piatt,E.J.,Wehrly,K.,Kuhmann,S.E.,Chesebro,B.and Kabat,D.(1998)Effects of CCR5 and CD4 cell surface concentrations on infection by macrophage tropic isolates of human immunodeficiency virus type 1.J.Virol.72,2855-2864.
40.Wei,X.,Decker,J.M.,Liu,H.,Zhang,Z.,Arani,R.B.,Kilby,J.M.,Saag,M.S.,Wu,X.,Shaw,G.M.and Kappes,J.C.(2002)Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20)monotherapy.Antimicrob.Agents Chemother.46,1896-1905.
41.Harouse JM,Buckner C,Gettie A,et al.CD8+ T cell-mediated CXC chemokine receptor 4-simian human immunodeficiency virus suppression in dually infected rhesus macaques.PNAS,2003,100:10977-10982.
42.Hollinger FB,Bremer JW,Myers LE,et al.Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group.The NIH/NIAID/DAIDS/ACTG Virology Laboratories.J.Clin.Microbiol.,1992;30(7):1787-1794.
43.Quinnan,G.V,P.F.Zhang,D.W.Fu,M.Dong,and J.B.Margolick.1998.Evolution of neutralizing antibody response against HIV type 1 virions and pseudovirions in multicenter AIDS cohort study participants.AIDS Res.Hum.Retrovir.14:939-949.
44.Montefiori,D.C.(2004)Evaluating neutralizing antibodies against HIV,SIV and SHIV in luciferase reporter gene assays.Current Protocols in Immunology,(Coligan,J.E.,A.M.Kruisbeek,D.H.Margulies,E.M.Shevach,W.Strober,and R.Coico,eds.),John Wiley & Sons,12.11.1-12.11.15.
45.Synthesis and anti-HIV-1 activity of 4-[4-(4,6-bisphenylamino-[1,3,5]triazin-2-ylamino)-5-methoxy-2-methylphenylazo]-5-hydroxynaphthalene-2,7-disulfonic acid and its derivatives Kannan P.Bioorganic & Medicinal Chemistry 12 (2004)1215-1220
46.Vodros D,Tscherning-Casper C,Navea L,Schols D,De Clercq E,Fenyo EM.Quantitative evaluation of HIV-1 coreceptor use in the GHOST3 cell assay.Virology.2001 Dec5;291(1):1-11
47.Sherry M.Owen,Donna Rudolph,Dominique Schols,Nobutaka Fujii,Naoki Yamamoto,and Renu B.Lall Susceptibility of Diverse Primary HIV Isolates With Varying Co-Receptor Specificity's to CXCR4 Antagonistic Compounds.Journal of Medical Virology,2002;68:147-155
48.邵一鸣,Horal P.中国及国外某些地区HIV感染者血清HIV1 gp120 V3肽反应的研究 中华微生物学和免疫学杂志1993;13(1):1-5
49.Li,M.,F.Gao,J.R.Mascola,L.Stamatatos,V.R.Polonis,M.Koutsoukos,G.Voss,P.Goepfert,P.Gilbert,K.M.Greene,M.Bilska,D.L.Kothe,J.F.Salazar-Gonzalez,X.Wei,J.M.Decker,B.H.Hahn,and D.C.Montefiori.2005.Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.J Virol 79:10108-25
50.Li,M.,J.F.Salazar-Gonzalez,C.A.Derdeyn,L.Morris,C.Williamson,J.E.Robinson,J.M.Decker,Y.Li,M.G.Salazar,V.R.Polonis,K.Mlisana,S.A.Karim,K.Hong,K.M.Greene,M.Bilska,J.Zhou,S.Allen,E.Chomba,J.Mulenga,C.Vwalika,F.Gao,M.Zhang,B.T.Korber,E.Hunter,B.H.Hahn,and D.C.Montefiori.2006.Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.J Virol 80:11776-90
51.Crooks GE,Hon G,Chandonia JM,Brenner SE(2004) WebLogo:a sequence logo generator.Genome Res 14:1188-1190
52.Schonning,K.,B.Jansson,S.Olofsson,and J.E.Hansen.1996.Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3loop of human immunodeficiency virus type 1.J Gen Virol 77(Pt 4):753-8.
53.Malenbaum,S.E.,D.YANG,and L.CAVACINI.2000.The N-Terminal V3 Loop Glycan Modulates the Interaction of Clade A and B Human Immunodeficiency Virus Type 1 Envelopes with CD4 and Chemokine Receptors.J Virol 74:11008-11016.
54.Ogert,R.A.,M.K.Lee,W.Ross,A.Buckler-White,M.A.Martin,and M.W.Cho.2001.N-linked glycosylation sites adjacent to and within the V1/V2 and the V3loops of dualtropic human immunodeficiency virus type 1 isolate DH 12 gp 120 affect coreceptor usage and cellular tropism.J Virol 75:5998-6006.
55.ShaoYM,ZhaoF,YangWZ,etal.The identification of recombinant HIV-1 strains in IDUs in southwest and northwest China.ChinJ Labandclinvirus,1999,13:109-112
56.Moore,J.P.,L.C.Burkly,R.I.Connor,Y,Cao,R.Tizard,D.D.Ho,and R.A.Fisher.1993.Adaptation of two primary human immunodeficiency virus type 1isolates to growth in transformed T cell lines correlates with alterations in the response of their envelope glycoproteins to soluble CD4.AIDS Res.Hum.Retrovir.9:529-539
57.Willey,R.L.,M.A.Martin,and K.W.C.Peden.1994.Increase in soluble CD4binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1.J.Virol.68:1029-1039.
58.Parren,P.W.,1998.Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1.J.Virol.72:10270-10274
59.Trkola,A.,H.Kuster,and P.Rusert.2008.In Vivo Efficacy of Human Immunodeficiency Virus Neutralizing Antibodies:Estimates for Protective Titers.J Virol 82:1591-1599.
60.Li,B.,J.M.Decker,R.W.Johnson,F.Bibollet-Ruche,X.Wei,J.Mulenga,S.Allen,E.Hunter,B.H.Hahn,G.M.Shaw,J.L.Blackwell,and C.A.Derdeyn.2006.Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1.J Virol 80:5211-8.
61.Wang,Q.,H.Shang,X.Han,Z.Zhang,Y.Jiang,Y.Wang,D.Dai,and Y.Diao.2008.High level serum neutralizing antibody against HIV-1 in Chinese long-term non-progressors.Microbiol Immunol 52:209-15.
62.Albert,J.,B.Abrahamsson,K.Nagy,E.Aurelius,H.Gaines,G.Nystrom,and E.M.Fenyo.1990.Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.Aids 4:107-12.
63.K Schonning,M Joost,GJ Gram,R Machuca,C Nielsen,JO Nielsen,and JE Hansen.Chemokine receptor polymorphism and autologous neutralizing antibody response in long-term HIV-1 infection.J Acquir Immune Defic Syndr Hum Retrovirol,1998;18(3):195-202.
64.Deeks,S.G,B.Schweighardt,T.Wrin,J.Galovich,R.Hoh,E.Sinclair,P.Hunt,J.M.McCune,J.N.Martin,C.J.Petropoulos,and F.M.Hecht.2006.Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV)infection:evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses.J Virol 80:6155-64
65.V Bongertz,CI Costa,VG Santos,EC Joao Filho,B Galvao-Castro,and MG Morgado.Correlation between susceptibility of primary HIV-1 isolates to autologous and heterologous neutralizing antibodies.Hospital Evandro Chagas AIDS Clinical Research Group.AIDS,1997;11(8):969-75.
66.Warren,R.Q.,S.A.Anderson,W.M.Nkya,J.F.Shao,C.W.Hendrix,G P.Melcher,R.R.Redfield,and R.C.Kennedy.1992.Examination of sera from human immunodeficiency virus type 1 (HlV-l)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.J Virol 66:5210-5
67.Ugolini,B.S.,I.Mondor,and P.W.H.I.Parren.1997.Inhibition of Virus Attachment to CD4 Target Cells Is a Major Mechanism of T Cell Line-adapted HIV-1 Neutralization.J.Exp.Med.:1287-1298.
68.Schonning,K.,O.Lund,O.S.Lund,and J.E.Hansen.1999.Stoichiometry of monoclonal antibody neutralization of T-cell line-adapted human immunodeficiency virus type 1.J Virol 73:8364-70.
69.Salzwedel,K.,J.T.West,and E.Hunter.1999.A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity.J Virol 73:2469-80.
70.Binley,J.,and J.P.Moore.1997.HlV-cell fusion.The viral mousetrap.Nature 387:346-8.
71.Ahmad A,Menezes J:Antibody-dependent cellular cytotoxicity in HIV infections.FASEBJ1996,10:258-266.
72.Ahmad R,Sindhu ST,Toma E,Morisset R,Vincelette J,Menezes J,Ahmad A:Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection.J Clin Immunol 2001,21:227-233.
73.Holl V,Peressin M,Decoville T,Schmidt S,Zolla-Pazner S,et al.Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells.J Virol,2006;80:6177-6181.
74.Hessell AJ,Hangartner L,Hunter M,HavenithCEG,Beurskens FJ,et al.Fc receptorbut not complement binding is important in antibody protection against HIV.Nature.2007;449:101-105.
75.Duval,M.,M.R.Posner,and L.A.Cavacini.2008.A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils.J Virol 82:4671-4
76.Edward Robinson,David C.Montefiori,William M.Mitchell,Alfred M.Prince,Harvey J.Alter,Gordon R.Dreesman,and Jorg W.Eichberg.Antibody-Dependent Enhancement of Human Immunodeficiency Virus Type 1 (HIV-1)Infection in vitro by Serum from HIV-1-Infected and Passively Immunized ChimpanzeesW.PNAS,1989;86:4710-4714
77.gamma R.A Takeda,R W Sweet,and F A Ennis.Two receptors are required for antibody-dependent enhancement of human immunodeficiency virus type 1 infection:CD4 and Fc J.Virol.,1990;64:5605-5610.
78.WE Robinson Jr,DC Montefiori,and WM Mitchell.Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors.Virology,1990;175(2):600-4.
79.Weber,J.,E.M.Fenyo,S.Beddows,P.Kaleebu,and A.Bjorndal.Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype.The WHO Network for HIV Isolation and Characterization.J Virol 1996.70:7827-32.
80.Chong,H.,K.Hong,C.Zhang,J.Nie,A.Song,W.Kong,and Y.Wang.2008.Genetic and Neutralization Properties of HIV-1 env Clones From Subtype B/BC/AE Infections in China.J Acquir Immune Defic Syndr 47:535-543.
81.Binley,J.M.,T.Wrin,and B.Korber.2004.Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1Monoclonal Antibodies.J Virol 78:13232-13252.
82.Derdeyn,C.A.,J.M.Decker,F.Bibollet-Ruche,J.L.Mokili,M.Muldoon,S.A.Denham,M.L.Heil,F.Kasolo,R.Musonda,B.H.Hahn,G.M.Shaw,B.T.Korber,S.Allen,and E.Hunter.2004.Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.Science 303:2019-22
83.Sagar,M.,X.Wu,S.Lee,and J.Overbaugh.2006.Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection,and these modifications affect antibody neutralization sensitivity.J Virol 80:9586-98.
84.Koch,M.,M.Pancera,P.D.Kwong,P.Kolchinsky,C.Grundner,L.Wang,W.A.Hendrickson,J.Sodroski,and R.Wyatt.2003.Structure-based,targeted deglycosylation of HIV-1 gp 120 and effects on neutralization sensitivity and antibody recognition.Virology 313:387-400.
85.Wei,X.,J.M.Decker,S.Wang,H.Hui,J.C.Kappes,X.Wu,J.F.Salazar-Gonzalez,M.G.Salazar,J.M.Kilby,M.S.Saag,N.L.Komarova,M.A.Nowak,B.H.Hahn,P.D.Kwong,and G.M.Shaw.2003.Antibody neutralization and escape by HIV-1.Nature 422:307-12.
86.Liu,S.,H.Xing,X.He,R.Xin,Y.Zhang,J.Zhu,and Y.Shao.2008.Analysis of Putative N-Linked Glycosylation Sites and Variable Region of Envelope HIV-1CRF07_BC Recombinant in Intravenous Drug Users in Xinjiang Autonomous Region,China.AIDS Res Hum Retroviruses 24:521-527.
87.Cham,F.,P.F.Zhang,L.Heyndrickx,P.Bouma,P.Zhong,H.Katinger,J.Robinson,G.van der Groen,and G.V.Quinnan,Jr.2006.Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.Virology 347:36-51.
88.Jensen,M.A.,F.S.Li,A.B.van't Wout,D.C.Nickle,D.Shriner,H.X.He,S.McLaughlin,R.Shankarappa,J.B.Margolick,and J.I.Mullins.2003.Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences.J Virol 77:13376-88
89.赵全璧 潘品良 温宁 等 中国艾滋病病毒1型流行毒株V3环序列变异性的研究 中国性病艾滋病防治2002,8(4):208-211
90.Ndung'u,T.,E.Sepako,M.F.McLane,F.Chand,K.Bedi,S.Gaseitsiwe,F.Doualla-Bell,T.Peter,I.Thior,S.M.Moyo,P.B.Gilbert,V.A.Novitsky,and M.Essex.2006.HIV-1 subtype C in vitro growth and coreceptor utilization.Virology 347:247-60.
91.Patel,M.B.,N.G.Hoffman,and R.Swanstrom.2008.Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins.J Virol 82:903-16.
92.Lusso,P.,P.L.Earl,F.Sironi,F.Santoro,C.Ripamonti,G.Scarlatti,R.Longhi,E.A.Berger,and S.E.Burastero.2005.Cryptic nature of a conserved,CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted,but not CXCR4-using,primary human immunodeficiency virus type 1 strains.J Virol 79:6957-68
93.Bunnik,E.M.,E.D.Quakkelaar,A.C.v.Nuenen,B.Boeser-Nunnink,and H.Schuitemaker.2007.Increased Neutralization Sensitivity of Recently Emerged CXCR4-Using Human Immunodeficiency Virus Type 1 Strains Compared to Coexisting CCR5-Using Variants from the Same Patient.J Virol:525-531
94.Cecilia,D.,V.N.KewalRamani,J.O'Leary,B.Volsky,P.Nyambi,S.Burda,S.Xu,D.R.Littman,and S.Zolla-Pazner.1998.Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage.J Virol 72:6988-96
95.Morris,M.K.,D.A.Katzenstein,D.Israelski,A.Zolopa,R.M.Hendry,and C.V.Hanson.2001.Characterization of the HIV-1 specific humoral immune response during highly active antiretroviral therapy (HAART).J Acquir Immune Defic Syndr 28:405-15
96.Bongertz,V,E.P.Ouverney,S.C.Fernandez,B.Grinsztejn,V.Veloso,J.C.Couto-Fernandez,J.H.Pilotto,and M.G Morgado.2007.Anti-human immunodeficiency virus type 1 humoral immune response and highly active antiretroviral treatment.Mem Inst Oswaldo Cruz 102:817-25.
1.Capon DJ,Ward RH.The CD4-gp120 interaction and AIDS pathogenesis.Annu Rev Immunol 1991;9:649-678
2.Bernstein HB,Tucker SP,Kar SR,et.al.Oligomerization of the hydrophobic heptad repeat of gp41.J Virol 1995;69:2745-2750.
3.Moore,J.P.,and J.Sodroski.1996.Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp 120 exterior envelope glycoprotein.J Virol 70:1863-72.
4.Kwong PD,Wyatt R,Robinson J.Structure of an HIV gp 120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.Nature.1998;393:648-59
5.Koch,M.,M.Pancera,P.D.Kwong,P.Kolchinsky,C.Grundner,L.Wang,W.A.Hendrickson,J.Sodroski,and R.Wyatt.2003.Structure-based,targeted deglycosylation of HIV-1 gp 120 and effects on neutralization sensitivity and antibody recognition.Virology 313:387-400.
6.Burton,D.R.,R.L.Stanfield,and I.A.Wilson.2005.Antibody vs.HIV in a clash of evolutionary titans.Proc Natl Acad Sci U S A 102:14943-8.
7.Kwong,P.D.,M.L.Doyle,D.J.Casper,C.Cicala,S.A.Leavitt,S.Majeed,T.D. Steenbeke,M.Venturi,I.Chaiken,M.Fung,H.Katinger,P.W.Parren,J.Robinson,D.Van Ryk,L.Wang,D.R.Burton,E.Freire,R.Wyatt,J.Sodroski,W.A.Hendrickson,and J.Arthos.2002.HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.Nature 420:678-82.
8.Krachmarov,C.P.,W.J.Honnen,S.C.Kayman,M.K.Gorny,S.Zolla-Pazner,and A.Pinter.2006.Factors Determining the Breadth and Potency of Neutralization by V3-Specific Human Monoclonal Antibodies Derived from Subjects Infected with Clade A or Clade B Strains of Human Immunodeficiency Virus Type 1.J Virol 80:7127-7135
9.Cao,J.,N.Sullivan,E.Desjardin,C.Parolin,J.Robinson,R.Wyatt,and J.Sodroski.1997.Replication and neutralization of human immunodeficiency virus type 1 lacking the VI and V2 variable loops of the gp120 envelope glycoprotein.J Virol 71:9808-12.
10.STAMATATOS,L.,and C.CHENG-MAYER.1998.An Envelope Modification That Renders a Primary,Neutralization-Resistant Clade B Human Immunodeficiency Virus Type 1 Isolate Highly Susceptible to Neutralization by Sera from Other Clades.J Virol 72:7840-7845.
11.Rong,R.,F.Bibollet-Ruche,J.Mulenga,S.Allen,J.L.Blackwell,and C.A.Derdeyn.2007.Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection.J Virol 81:1350-9
12.Lue,J.,M.Hsu,D.Yang,P.Marx,Z.Chen,and C.Cheng-Mayer.2002.Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1.J Virol 76:10299-306.
13.Ching,L.K.,G.Vlachogiannis,K.A.Bosch,and L.Stamatatos.2008.The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen.J Virol 82:949-56.
14.Li,Y,B.Cleveland,I.Klots,B.Travis,B.A.Richardson,D.Anderson,D.Montefiori,P.Polacino,and S.L.Hu.2008.Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses.J Virol 82:638-51
15.Beaumont,T.,E.Quakkelaar,A.van Nuenen,R.Pantophlet,and H.Schuitemaker.2004.Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus ⅢB strain isolated from an accidentally infected laboratory worker.J Virol 78:5651-7
16.Wolk,T.,and M.Schreiber.2006.N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization.Med Microbiol Immunol 195:165-72
17.Broliden,P.A.,B.Makitalo,L.Akerblom,J.Rosen,K.Broliden,G.Utter,M.Jondal,E.Norrby,and B.Wahren.1991.Identification of amino acids in the V3 region of gp120 critical for virus neutralization by human HIV-1-specific antibodies.Immunology 73:371-6
18.Spear,G.T.,D.M.Takefman,S.Sharpe,M.Ghassemi,and S.Zolla-Pazner.1994.Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation,antibody binding,and neutralization.Virology 204:609-15.
19.Kim,Y.B.,D.P.Han,C.Cao,and M.W.Cho.2003.Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies.Virology 305:124-37.
20.Bell,C.H.,R.Pantophlet,A.Schiefner,L.A.Cavacini,R.L.Stanfield,D.R.Burton,and I.A.Wilson.2008.Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization.J Mol Biol 375:969-78
21.Malenbaum,S.E.,D.YANG,and L.CAVACINI.2000.The N-Terminal V3 Loop Glycan Modulates the Interaction of Clade A and B Human Immunodeficiency Virus Type 1 Envelopes with CD4 and Chemokine Receptors.J Virol 74:11008-11016.
22.McCaffrey,R.A.,C.Saunders,M.Hensel,and L.Stamatatos.2004.N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.J Virol 78:3279-95.
23.Liang,H.,M.Wei,Z.Chen,H.Xing,Q.B.Zhao,Y.Feng,Q.Guan,L.Y.Shi,and Y.M.Shao.2003.[Sequence variation in the env V3-V4 region of HIV type 1 predominant subtype B and C strains circulating in China].Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 17:153-8.
24.Liang,H.,H.Xing,J.Z.Li,M.Wei,K.X.Hong,Y.Feng,Q.B.Zhao,J.P.Chen,Y.Quan,T.Teng,and Y M.Shao.2005.[Identification of signature amino acids in the env V3-V4 and flanking regions of human immunodeficiency virus type 1 predominant strains in China].Zhonghua Yi Xue Za Zhi 85:897-902.
25.Moore,P.L.,E.S.Gray,and I.A.Choge.2008.The C3-V4 Region Is a Major Target of Autologous Neutralizing Antibodies in Human Immunodeficiency Virus Type 1 Subtype C Infection.J Virol 82:1860-1869.
26.Castro,E.,M.Belair,G.P.Rizzardi,P.A.Bart,G.Pantaleo,and C.Graziosi.2008.Independent evolution of hypervariable regions of HIV-1 gp120:V4 as a swarm of N-Linked glycosylation variants.AIDS Res Hum Retroviruses 24:106-13.
27.Sanders,R.W,E.van Anken,A.A.Nabatov,I.M.Liscaljet,I.Bontjer,D.Eggink,M.Melchers,E.Busser,M.M.Dankers,F.Groot,I.Braakman,B.Berkhout,and W.A.Paxton.2008.The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion.Retrovirology 5:10.
28.Gnanakaran,S.,D.Lang,M.Daniels,T.Bhattacharya,C.A.Derdeyn,and B.Korber.2007.Clade-specific differences between human immunodeficiency virus type 1 clades B and C:diversity and correlations in C3-V4 regions of gp120.J Virol 81:4886-91.
29.Harrington,P.R.,J.A.E.Nelson,K.M.Kitrinos,and R.Swanstrom.2007.Independent Evolution of Human Immunodeficiency Virus Type 1 env V1/V2 and V4/V5 Hypervariable Regions during Chronic Infection.J Virol 81:5413-5417.
30.Nygren,A.,T.Bergman,T.Matthews,H.Jornvall,and H.Wigzell.1988.95-and 25-kDa fragments of the human immunodeficiency virus envelope glycoprotein gp120 bind to the CD4 receptor.Proc Natl Acad Sci U S A 85:6543-6.
31.Chan,S.Y.,R.F.Speck,C.Power,S.L.Gaffen,B.Chesebro,and M.A.Goldsmith.1999.V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1.J Virol 73:2350-8.
32.Pastore,C,R.Nedellec,A.Ramos,S.Pontow,L.Ratner,and D.E.Mosier.2006.Human immunodeficiency virus type 1 coreceptor switching:V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.J Virol 80:750-8.
33.Kiselyeva,Y,R.Nedellec,A.Ramos,C.Pastore,L.B.Margolis,and D.E.Mosier.2007.Evolution of CXCR4-using human immunodeficiency virus type 1 SF162 is associated with two unique envelope mutations.J Virol 81:3657-61
34.Wyatt,R.,N.Sullivan,M.Thali,H.Repke,D.Ho,J.Robinson,M.Posner,and J.Sodroski.1993.Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions.J Virol 67:4557-65
35.Wyatt,R.,J.Moore,M.Accola,E.Desjardin,J.Robinson,and J.Sodroski.1995.Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.J Virol 69:5723-33
36.Feng,Y,C.C.Broder,P.E.Kennedy,and E.A.Berger.1996.HIV-1 entry cofactor:functional cDNA cloning of a seven-transmembrane,G protein-coupled receptor.Science 272:872-7.
37.Deng,H.,R.Liu,W.Ellmeier,S.Choe,D.Unutmaz,M.Burkhart,P.Di Marzio,S.Marmon,R.E.Sutton,C.M.Hill,C.B.Davis,S.C.Peiper,T.J.Schall,D.R.Littman,and N.R.Landau.1996.Identification of a major co-receptor for primary isolates of HIV-1.Nature 381:661-6.
38.Dragic,T.,V.Litwin,G.P.Allaway,S.R.Martin,Y.Huang,K.A.Nagashima,C.Cayanan,P.J.Maddon,R.A.Koup,J.P.Moore,and W.A.Paxton.1996.HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.Nature 381:667-73.
39.Berger,E.A.,R.W.Doms,E.M.Fenyo,B.T.Korber,D.R.Liftman,J.P.Moore,Q.J.Sattentau,H.Schuitemaker,J.Sodroski,and R.A.Weiss.1998.A new classification for HIV-1.Nature 391:240.
40.Alkhatib,G,C.Combadiere,C.C.Broder,Y.Feng,P.E.Kennedy,P.M.Murphy,and E.A.Berger.1996.CC CKR5:a RANTES,MIP-1 alpha,MlP-lbeta receptor as a fusion cofactor for macrophage-tropic HIV-1.Science 272:1955-8
41.Cilliers,T.,and L.Morris.2002.Coreceptor usage and biological phenotypes of HIV-1 isolates.Clin Chem Lab Med 40:911-7.
42.Hartley,O.,P.J.Klasse,Q.J.Sattentau,and J.P.Moore.2005.V3:HIV's switch-hitter.AIDS Res Hum Retroviruses 21:171-89.
43.Nabatov,A.A.,G.Pollakis,T.Linnemann,A.Kliphius,M.I.Chalaby,and W.A.Paxton.2004.Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage,virus inhibition by CC/CXC chemokines,soluble CD4,and the b 12 and 2G12 monoclonal antibodies.J Virol 78:524-30.
44.Hwang,S.S.,T.J.Boyle,H.K.Lyerly,and B.R.Cullen.1991.Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1.Science 253:71-4
45.Garrido,C,V.Roulet,N.Chueca,E.Poveda,A.Aguilera,K.Skrabal,N.Zahonero,S.Carlos,F.Garcia,J.L.Faudon,V Soriano,and C.de Mendoza.2008.Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes.J Clin Microbiol 46:887-91.
46.Jensen,M.A.,and A.B.van 't Wout.2003.Predicting HIV-1 coreceptor usage with sequence analysis.AIDS Rev,5:104-12.
47.Saracino,A.,L.Monno,G Punzi,D.C.Cibelli,A.Tartaglia,L.Scudeller,G.Brindicci,A.Lagioia,G Scotto,and G Angarano.2007.HIV-1 biological phenotype and predicted coreceptor usage based on V3 loop sequence in paired PBMC and plasma samples.Virus Res 130:34-42.
48.Kato,K.,H.Sato,and Y.Takebe.1999.Role of naturally occurring basic amino acid substitutions in the human immunodeficiency virus type 1 subtype E envelope V3 loop on viral coreceptor usage and cell tropism.J Virol 73:5520-6.
49.Jensen,M.A.,F.S.Li,A.B.van 't Wout,D.C.Nickle,D.Shriner,H.X.He,S.McLaughlin,R.Shankarappa,J.B.Margolick,and J.I.Mullins.2003.Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences.J Virol 77:13376-88.
50.Rosen,O.,A.O.Samson,and J.Anglister.2008.Correlated mutations at gp120 positions 322 and 440:Implications for gp120 structure.Proteins 71:1066-1070
51.Geijtenbeek,T.B.,D.S.Kwon,R.Torensma,S.J.van Vliet,G.C.van Duijnhoven,J.Middel,I.L.Cornelissen,H.S.Nottet,V.N.KewalRamani,D.R.Littman,C.G.Figdor,and Y.van Kooyk.2000.DC-SIGN,a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells.Cell 100:587-97.
52.Chan,D.C,D.Fass,J.M.Berger,and P.S.Kim.1997.Core structure of gp41 from the HIV envelope glycoprotein.Cell 89:263-73.
53.Zwick,M.B.,R.Jensen,S.Church,M.Wang,G.Stiegler,R.Kunert,H.Katinger,and D.R.Burton.2005.Anti-human immunodeficiency virus type 1 (HIV-1)antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.J Virol 79:1252-61.
54.Park,E.J.,M.K.Gorny,S.Zolla-Pazner,and G.V.Quinnan,Jr.2000.A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.J Virol 74:4183-91
55.Watkins,B.A.,S.Buge,K.Aldrich,A.E.Davis,J.Robinson,M.S.Reitz,Jr.,and M.Robert-Guroff.1996.Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites.J Virol 70:8431-7.
56.Kalia,V,S.Sarkar,P.Gupta,and R.C.Montelaro.2005.Antibody neutralization escape mediated by point mutations in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41.J Virol 79:2097-107.
57.Blish,C.A.,M.A.Nguyen,and J.Overbaugh.2008.Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41.PLoS Med 5:e9.
58.Montero,M.,N.E.van Houten,X.Wang,and J.K.Scott.2008.The membrane-proximal external region of the human immunodeficiency virus type 1 envelope:dominant site of antibody neutralization and target for vaccine design.Microbiol Mol Biol Rev 72:54-84
59.Gray,E.S.,P.L.Moore,F.Bibollet-Ruche,H.Li,J.M.Decker,T.Meyers,G.M.Shaw,and L.Morris.2008.4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response.J Virol 82:2367-75.
60.Pikora,C.A.2004.Glycosylation of the ENV spike of primate immunodeficiency viruses and antibody neutralization.Curr HIV Res 2:243-54.
61.Wyatt R.,Sodroski J.The HIV-1 envelope glycoproteins:fusogens,antigens,and immunogens.Science 1998;280 (5371):1884-1888.
62.Wei,X.,J.M.Decker,S.Wang,H.Hui,J.C.Kappes,X.Wu,J.F.Salazar-Gonzalez,M.G Salazar,J.M.Kilby,M.S.Saag,N.L.Komarova,M.A.Nowak,B.H.Hahn,P.D.Kwong,and G.M.Shaw.2003.Antibody neutralization and escape by HIV-1.Nature 422:307-12.
63.Ogert,R.A.,M.K.Lee,W.Ross,A.Buckler-White,M.A.Martin,and M.W.Cho.2001.N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dual tropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism.J Virol 75:5998-6006.
64.Reynard,F.,A.Fatmi,B.Verrier,and F.Bedin.2004.HIV-1 acute infection env glycomutants designed from 3D model:effects on processing,antigenicity,and neutralization sensitivity.Virology 324:90-102.
65.Li,H.,P.C.Chien,Jr.,M.Tuen,M.L.Visciano,S.Cohen,S.Blais,C.F.Xu,H.T.Zhang,and C.E.Hioe.2008.Identification of an N-linked glycosylation in the C4 region of HIV-1 envelope gp120 that is critical for recognition of neighboring CD4 T cell epitopes.J Immunol 180:4011-21.
1.Moore JP and Stevenson M.New targets for inhibitors of HIV-1 replication[J].Nat Rev Mol Cell Biol,2000;1(1):40-49.
2.Fletcher CV.Enfuvirtide,a new drug for HIV infection[J].Lancet,2003;361(9369):1577-1578.
3.Wu Hao,Myszka DG,Tendian SW,et al.Kinetic and structural analysis of mutant CD4 receptors that are defective in HIVgpl20binding[J].Proc Natl Acad Sci USA,1996;93:15030-15035.
4.MadaniN,PerdigotoAL,Srinivasan K,et al.Localized Changes in the gp120Envelope Glycoprotein Confer Resistance to Human Immunodeficiency Virus Entry Inhibitors BMS-806 and #155[J].J.Virol,2004;78:3742-3752.
5.Jacobson JM,Lowy I,Fletcher CV,et al.Single-dose safety,pharmacology,and antiviral activity of the human immunodeficiency virus(HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults[J].J Infect Dis,2000;182(1):326-329.
6.Moore PL,Cilliers T,Morris L.Predicted genotypic resistance to the novel entry inhibitor,BMS-378806,among HIV-1 isolates of subtypes A to G[J].AIDS,2004;18(17):2327-2330..
7.Schols D.HIV co-receptor inhibitors as novel class of anti-HIV drugs[J].Antiviral Res,2006;71(2-3):216-226.
8.FDA Approval:Maraviroc AIDS Clinical Care,2007;2007:1.
9.Trkola A,Ketas TJ,Nagashima KA,et al.Potent,broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140[J].J.Virol,2001,75(2):579-588.
10.Dragic T,Trkola A,Thompson D.et al.A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5[J].Proc Natl Acad Sci USA,2000;97:5639-5644.
11.Trkola A,Kuhmann SE,Strizki JM,et al.HIV-1 escape from a small molecule,CCR5-specific entry inhibitor does not involve CXCR4use[J].PNAS,2002;99:395-400.
12.Maeda Y,Foda M,Matsushita S,et al.Involvement of both the V2 and V3 Regions of the CCR5-Tropic Human Immunodeficiency Virus Type 1 Envelope in Reduced Sensitivity to Macrophage Inflammatory Protein 1α[J].J.Virol.,2000;74:1787-1793.
13.Mosier DE,Picchio GR,Gulizia RJ,et al.Highly Potent RANTES Analogues either Prevent CCR5-Using Human Immunodeficiency Virus Type 1 Infection In Vivo or Rapidly Select for CXCR4-Using Variants[J].J.Virol,1999;73:3544-3550.
14 Westby M,Smith-Burchnell C,Mori J,et al.Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry J.Virol.,2007;81:2359-2371.
15.Schols D,.Este JA,Cabrera C,et al.T-Cell-Line-Tropic Human Immunodeficiency Virus Type 1 That Is Made Resistant to Stromal Cell-Derived Factor la Contains Mutations in the Envelope gp120 but Does Not Show a Switch in CoreceptorUse [J].J.Virol.,1998;72:4032-4037.
16.Vreese K,Kofler-Mongold V,Leutgeb C,et al.The molecular target of bicyclams,potent inhibitors of human immunodeficiency virus replication[J]J.Virol,1996;70:689-696.
17.Nolan KM,Jordan A,and.Hoxie JA.Effects of Partial Deletions within the HIV-1 V3 Loop on Coreceptor Tropism and Sensitivity to Entry Inhibitors[J]J.Virol.,2007;10.1128/JVI.01793-07
18.Welch BD,VanDemark AP,Heroux A,Potent D-peptide inhibitors of HIV-1 entry[J].Proc Natl Acad Sci,2007;43:16828-16838
19.RootMJ,KayMS,Kim PS.Protein design of an HIV-1 entry inhibitor[J].Science,2001;291(5505):884-888.
20.Munch J,StandkerL,Adermann K,Discovery and Optimization of a Natural HIV-1 Entry Inhibitor Targeting the gp41 Fusion Peptide[J].cell,2007;129:263-275
21.Sista PR,Melby T,Davison D,et al.Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates[J].AIDS,2004;18(13):1787-94.
22.Johnson VA,Brun-Vezinet F,Clotet B,et al.Update of the drug resistance mutations in HIV-1:Fall 2006[J].Top HIV Med,2006;14(3):125-30
23.Heredia A,Gilliam B,DeVico A,et al.CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1[J].AIDS,2007;21(10):1317-22.
24.Reeves J,Gallo S,Ahmad N,et al.Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity,receptor density,and fusion kinetics[J].Proc Natl Acad Sci USA,2002;99:16249-54.
25.Ray N,Harrison JE,Blackburn L,et al.Clinical Resistance to Enfuvirtide Does Not Affect Susceptibility of Human Immunodeficiency Virus Type 1 to Other Classes of Entry Inhibitors[J].J.Virol,2007;81:3240-3250.